Fresh approach to 100 years of pain relief


    - ASPIRIN(R) Express Pack(TM) in stores now -

    TORONTO, April 3 /CNW/ - Bayer Inc., one of Canada's leading healthcare
companies, has launched ASPIRIN(R) Express Pack(TM) in the Canadian
over-the-counter market.
    ASPIRIN Express Pack's special granular format dissolves quickly and the
product provides consumers with rapid pain relief from headaches, fever, joint
and body pain. Contained in a convenient sachet form, the 500 mg of
quick-dissolve acetylsalicylic acid (ASA) granules does not necessarily need
to be taken with water, but can be taken with water if desired, making quick
pain relief even more convenient.
    "ASPIRIN Express Pack demonstrates Bayer's commitment to innovation and
to providing our customers with new products for pain management," said Kevin
Skinner, Country Division Head, Bayer HealthCare, Consumer Care.
    ASPIRIN Express Pack is the newest addition to the ASPIRIN portfolio that
includes ASPIRIN 81mg for doctor supervised long term preventative therapy,
and ASPIRIN Night-Time that works to reduce tense muscles, muscle spasms, and
the pain. ASPIRIN Express Pack is available in retail pharmacies across
Canada.

    About Bayer Inc.

    Bayer Inc. (Bayer) is a Canadian subsidiary of Bayer AG, an international
research-based group with core businesses in health care, crop science, and
innovative materials.
    Headquartered in Toronto, Ontario, Bayer Inc. operates the Bayer Group's
HealthCare and Material Science businesses in Canada. Bayer CropScience Inc.,
headquartered in Calgary, Alberta operates as a separate legal entity in
Canada. Together, the companies play a vital role in improving the quality of
life for Canadians - producing products that fight diseases, protecting crops
and animals, and developing high-performance materials for applications in
numerous areas of daily life.
    Canadian Bayer facilities include the Toronto headquarters and offices in
Ottawa and Calgary. Bayer Inc. has approximately 1,000 employees across Canada
and had sales of over $910 million CDN in 2006. Globally, the Bayer Group had
sales of over 28 billion Euro in 2006.
    Bayer Inc. invested approximately $47 million CDN in research and
development in 2006. Worldwide, the Bayer Group spends the equivalent of over
2 billion Euro in 2006 in R&D.



For further information: Alison Bing, Bayer Inc., (416) 240-5298,
alison.bing.b@bayer.com